Sequential chemotherapy in nonsmall-cell lung cancer: Cisplatin and gemcitabine followed by docetaxel

Anna Ceribelli, Maria S. Pino, Alain J. Gelibter, Michele Milella, Fabiana L. Cecere, Mauro Caterino, Francesco Facciolo, Alessandra Mirri, Francesco Cognetti

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Improving results in nonsmall-cell lung cancer (NSCLC) will require the development of new drugs and strategies to combine available agents. On the basis of data indicating the activity of docetaxel as second-line therapy, a Phase II study was conducted to evaluate the efficacy and toxicity of the sequential combination of chemotherapy consisting of cisplatin (P) and gemcitabine (G) followed by docetaxel (DOC) in patients with advanced NSCLC. METHODS. Patients with 1997 TNM stage IIIB (pleural effusion)/stage IV NSCLC, performance status (PS) of 0-1, and normal organ function were eligible. Therapy consisted of P at 75 mg/m2 on Day 1 and G 1200 mg/m2 on Days 1 and 8 every 3 weeks for 3 cycles followed, in nonprogressive patients, by DOC 30 mg/m2 every week for 6 consecutive weeks every 8 weeks for 2 cycles. RESULTS. Fifty-two eligible patients were enrolled (M/F, 39/13; stage IIIB/IV, 8/44; PS 0, 73%, PS 1, 27%; median age, 58 years; range, 36-73). The overall response rate was 36.5% (95% confidence interval [CI]: 23-49). The median overall survival was 11 months (95% CI: 9-13); the median progression-free survival was 6 months (95% CI: 5-7); and the 1- and 2-year survivals were 48% and 25%, respectively. One- and 2-year progression-free survivals were 12% and 8%, respectively. Both phases of the treatment protocol were well tolerated. CONCLUSIONS. P/G followed by weekly DOC is well tolerated and active as first-line therapy for NSCLC patients and provides a feasible chemotherapeutic option in this clinical setting.

Original languageEnglish
Pages (from-to)727-731
Number of pages5
JournalCancer
Volume109
Issue number4
DOIs
Publication statusPublished - Feb 15 2007

Fingerprint

docetaxel
gemcitabine
Non-Small Cell Lung Carcinoma
Cisplatin
Drug Therapy
Confidence Intervals
Disease-Free Survival
Survival
Pleural Effusion
Clinical Protocols
Combination Drug Therapy
Therapeutics

Keywords

  • Nonsmall-cell lung cancer
  • NSCLC
  • Sequential chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sequential chemotherapy in nonsmall-cell lung cancer : Cisplatin and gemcitabine followed by docetaxel. / Ceribelli, Anna; Pino, Maria S.; Gelibter, Alain J.; Milella, Michele; Cecere, Fabiana L.; Caterino, Mauro; Facciolo, Francesco; Mirri, Alessandra; Cognetti, Francesco.

In: Cancer, Vol. 109, No. 4, 15.02.2007, p. 727-731.

Research output: Contribution to journalArticle

Ceribelli, Anna ; Pino, Maria S. ; Gelibter, Alain J. ; Milella, Michele ; Cecere, Fabiana L. ; Caterino, Mauro ; Facciolo, Francesco ; Mirri, Alessandra ; Cognetti, Francesco. / Sequential chemotherapy in nonsmall-cell lung cancer : Cisplatin and gemcitabine followed by docetaxel. In: Cancer. 2007 ; Vol. 109, No. 4. pp. 727-731.
@article{1ac423c21649468ab1638cf1caa16310,
title = "Sequential chemotherapy in nonsmall-cell lung cancer: Cisplatin and gemcitabine followed by docetaxel",
abstract = "BACKGROUND. Improving results in nonsmall-cell lung cancer (NSCLC) will require the development of new drugs and strategies to combine available agents. On the basis of data indicating the activity of docetaxel as second-line therapy, a Phase II study was conducted to evaluate the efficacy and toxicity of the sequential combination of chemotherapy consisting of cisplatin (P) and gemcitabine (G) followed by docetaxel (DOC) in patients with advanced NSCLC. METHODS. Patients with 1997 TNM stage IIIB (pleural effusion)/stage IV NSCLC, performance status (PS) of 0-1, and normal organ function were eligible. Therapy consisted of P at 75 mg/m2 on Day 1 and G 1200 mg/m2 on Days 1 and 8 every 3 weeks for 3 cycles followed, in nonprogressive patients, by DOC 30 mg/m2 every week for 6 consecutive weeks every 8 weeks for 2 cycles. RESULTS. Fifty-two eligible patients were enrolled (M/F, 39/13; stage IIIB/IV, 8/44; PS 0, 73{\%}, PS 1, 27{\%}; median age, 58 years; range, 36-73). The overall response rate was 36.5{\%} (95{\%} confidence interval [CI]: 23-49). The median overall survival was 11 months (95{\%} CI: 9-13); the median progression-free survival was 6 months (95{\%} CI: 5-7); and the 1- and 2-year survivals were 48{\%} and 25{\%}, respectively. One- and 2-year progression-free survivals were 12{\%} and 8{\%}, respectively. Both phases of the treatment protocol were well tolerated. CONCLUSIONS. P/G followed by weekly DOC is well tolerated and active as first-line therapy for NSCLC patients and provides a feasible chemotherapeutic option in this clinical setting.",
keywords = "Nonsmall-cell lung cancer, NSCLC, Sequential chemotherapy",
author = "Anna Ceribelli and Pino, {Maria S.} and Gelibter, {Alain J.} and Michele Milella and Cecere, {Fabiana L.} and Mauro Caterino and Francesco Facciolo and Alessandra Mirri and Francesco Cognetti",
year = "2007",
month = "2",
day = "15",
doi = "10.1002/cncr.22480",
language = "English",
volume = "109",
pages = "727--731",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Sequential chemotherapy in nonsmall-cell lung cancer

T2 - Cisplatin and gemcitabine followed by docetaxel

AU - Ceribelli, Anna

AU - Pino, Maria S.

AU - Gelibter, Alain J.

AU - Milella, Michele

AU - Cecere, Fabiana L.

AU - Caterino, Mauro

AU - Facciolo, Francesco

AU - Mirri, Alessandra

AU - Cognetti, Francesco

PY - 2007/2/15

Y1 - 2007/2/15

N2 - BACKGROUND. Improving results in nonsmall-cell lung cancer (NSCLC) will require the development of new drugs and strategies to combine available agents. On the basis of data indicating the activity of docetaxel as second-line therapy, a Phase II study was conducted to evaluate the efficacy and toxicity of the sequential combination of chemotherapy consisting of cisplatin (P) and gemcitabine (G) followed by docetaxel (DOC) in patients with advanced NSCLC. METHODS. Patients with 1997 TNM stage IIIB (pleural effusion)/stage IV NSCLC, performance status (PS) of 0-1, and normal organ function were eligible. Therapy consisted of P at 75 mg/m2 on Day 1 and G 1200 mg/m2 on Days 1 and 8 every 3 weeks for 3 cycles followed, in nonprogressive patients, by DOC 30 mg/m2 every week for 6 consecutive weeks every 8 weeks for 2 cycles. RESULTS. Fifty-two eligible patients were enrolled (M/F, 39/13; stage IIIB/IV, 8/44; PS 0, 73%, PS 1, 27%; median age, 58 years; range, 36-73). The overall response rate was 36.5% (95% confidence interval [CI]: 23-49). The median overall survival was 11 months (95% CI: 9-13); the median progression-free survival was 6 months (95% CI: 5-7); and the 1- and 2-year survivals were 48% and 25%, respectively. One- and 2-year progression-free survivals were 12% and 8%, respectively. Both phases of the treatment protocol were well tolerated. CONCLUSIONS. P/G followed by weekly DOC is well tolerated and active as first-line therapy for NSCLC patients and provides a feasible chemotherapeutic option in this clinical setting.

AB - BACKGROUND. Improving results in nonsmall-cell lung cancer (NSCLC) will require the development of new drugs and strategies to combine available agents. On the basis of data indicating the activity of docetaxel as second-line therapy, a Phase II study was conducted to evaluate the efficacy and toxicity of the sequential combination of chemotherapy consisting of cisplatin (P) and gemcitabine (G) followed by docetaxel (DOC) in patients with advanced NSCLC. METHODS. Patients with 1997 TNM stage IIIB (pleural effusion)/stage IV NSCLC, performance status (PS) of 0-1, and normal organ function were eligible. Therapy consisted of P at 75 mg/m2 on Day 1 and G 1200 mg/m2 on Days 1 and 8 every 3 weeks for 3 cycles followed, in nonprogressive patients, by DOC 30 mg/m2 every week for 6 consecutive weeks every 8 weeks for 2 cycles. RESULTS. Fifty-two eligible patients were enrolled (M/F, 39/13; stage IIIB/IV, 8/44; PS 0, 73%, PS 1, 27%; median age, 58 years; range, 36-73). The overall response rate was 36.5% (95% confidence interval [CI]: 23-49). The median overall survival was 11 months (95% CI: 9-13); the median progression-free survival was 6 months (95% CI: 5-7); and the 1- and 2-year survivals were 48% and 25%, respectively. One- and 2-year progression-free survivals were 12% and 8%, respectively. Both phases of the treatment protocol were well tolerated. CONCLUSIONS. P/G followed by weekly DOC is well tolerated and active as first-line therapy for NSCLC patients and provides a feasible chemotherapeutic option in this clinical setting.

KW - Nonsmall-cell lung cancer

KW - NSCLC

KW - Sequential chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=33846938334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846938334&partnerID=8YFLogxK

U2 - 10.1002/cncr.22480

DO - 10.1002/cncr.22480

M3 - Article

C2 - 17238182

AN - SCOPUS:33846938334

VL - 109

SP - 727

EP - 731

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -